The tat inhibitor didehydro-cortistatin a prevents HIV-1 reactivation from latency

mBio

Volumn 6, Issue 4, 2015, Pages

  Mousseau, Guillaume ^a   Kessing, Cari F ^a,b   Fromentin, Rémi ^b,c   Trautmann, Lydie ^b   Chomont, Nicolas ^b,c   Valente, Susana T ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Vaccine and Gene Therapy Institute of Florida ^*  (United States)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD28 ANTIGEN; CD3 ANTIGEN; CORTISTATIN; DIDEHYDROCORTISTATIN A; EFAVIRENZ; LAMIVUDINE; RALTEGRAVIR; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDEHYDRO-CORTISTATIN A; FUSED HETEROCYCLIC RINGS; ISOQUINOLINE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEEDBACK SYSTEM; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION REGULATION; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS TRANSCRIPTION; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; METABOLISM; PHYSIOLOGY; VIROLOGY;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, VIRAL; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HIV-1; HUMANS; ISOQUINOLINES; PROMOTER REGIONS, GENETIC; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS LATENCY;

EID: 84940853263     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00465-15     Document Type: Article

References (91)

1. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF. 1995. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1:1284–1290. http://dx.doi.org/10.1038/nm1295-1284
2. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 94:13193–13197. http://dx.doi.org/10.1073/pnas.94.24.13193
3. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295–1300. http://dx.doi.org/10.1126/science.278.5341.1295
4. Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291–1295. http://dx.doi.org/10.1126/science.278.5341.1291
5. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF. 1999. Latent infection of CD4+T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5:512–517. http://dx.doi.org/10.1038/8394
6. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF. 2003. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9:727–728. http://dx.doi.org/10.1038/nm880
7. Buzón MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, Gatell JM, Domingo P, Paredes R, Sharkey M, Palmer S, Stevenson M, Clotet B, Blanco J, Martinez-Picado J. 2010. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAARTsuppressed subjects. Nat Med 16:460–465. http://dx.doi.org/10.1038/nm.2111
8. Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG, Beilman GJ, Khoruts A, Thorkelson A, Schmidt TE, Anderson J, Perkey K, Stevenson M, Perelson AS, Douek DC, Haase AT, Schacker TW. 2014. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A 111: 2307–2312. http://dx.doi.org/10.1073/pnas.1318249111
9. Hatano H, Strain MC, Scherzer R, Bacchetti P, Wentworth D, Hoh R, Martin JN, McCune JM, Neaton JD, Tracy RP, Hsue PY, Richman DD, Deeks SG. 2013. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis 208: 1436–1442. http://dx.doi.org/10.1093/infdis/jit453
10. Besson GJ, McMahon D, Maldarelli F, Mellors JW. 2012. Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy. Clin Infect Dis 54:451–453. http://dx.doi.org/10.1093/cid/cir721
11. Kearney MF, Spindler J, Shao W, Yu S, Anderson EM, O’Shea A, Rehm C, Poethke C, Kovacs N, Mellors JW, Coffin JM, Maldarelli F. 2014. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog 10:e1004010. http://dx.doi.org/10.1371/journal.ppat.1004010
12. Deeks SG, Lewin SR, Havlir DV. 2013. The end of AIDS: HIV infection as a chronic disease. Lancet 382:1525–1533. http://dx.doi.org/10.1016/S0140-6736(13)61809-7
13. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, O’Shea A, Callender M, Spivak A, Brennan T, Kearney MF, Proschan MA, Mican JM, Rehm CA, Coffin JM, Mellors JW, Siliciano RF, Maldarelli F. 2009. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 106:9403–9408. http://dx.doi.org/10.1073/pnas.0903107106
14. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, Kallungal B, Palmer S, Medvik K, Lederman MM, Alatrakchi N, Jacobson JM, Wiegand A, Kearney M, Coffin JM, Mellors JW, Eron JJ, AIDS Clinical Trials Group A5244 Team. 2010. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 7:e1000321. http://dx.doi.org/10.1371/journal.pmed.1000321
15. Okamoto T, Wong-Staal F. 1986. Demonstration of virus-specific transcriptional activator(s) in cells infected with HTLV-III by an in vitro cell-free system. Cell 47:29–35. http://dx.doi.org/10.1016/0092-8674(86)90363-6
16. Selby MJ, Bain ES, Luciw PA, Peterlin BM. 1989. Structure, sequence, and position of the stem-loop in TAR determine transcriptional elongation by tat through the HIV-1 long terminal repeat. Genes Dev 3:547–558. http://dx.doi.org/10.1101/gad.3.4.547
17. Laspia MF, Rice AP, Mathews MB. 1989. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell 59:283–292. http://dx.doi.org/10.1016/0092-8674(89)90290-0
18. Mancebo HS, Lee G, Flygare J, Tomassini J, Luu P, Zhu Y, Peng J, Blau C, Hazuda D, Price D, Flores O. 1997. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev 11: 2633–2644. http://dx.doi.org/10.1101/gad.11.20.2633
19. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA. 1998. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92: 451–462. http://dx.doi.org/10.1016/S0092-8674(00)80939-3
20. Karn J. 2011. The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit. Curr Opin HIV AIDS 6:4–11. http://dx.doi.org/10.1097/COH.0b013e328340ffbb
21. Ott M, Geyer M, Zhou Q. 2011. The control of HIV transcription: keeping RNA polymerase II on track. Cell Host Microbe 10:426–435. http://dx.doi.org/10.1016/j.chom.2011.11.002
22. Ghose R, Liou LY, Herrmann CH, Rice AP. 2001. Induction of TAK (cyclin T1/P-TEFb) in purified resting CD4(_) T lymphocytes by combination of cytokines. J Virol 75:11336–11343. http://dx.doi.org/10.1128/JVI.75.23.11336-11343.2001
23. Kinoshita S, Chen BK, Kaneshima H, Nolan GP. 1998. Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Cell 95:595–604. http://dx.doi.org/10.1016/S0092-8674(00)81630-X
24. Nabel G, Baltimore D. 1987. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326: 711–713. http://dx.doi.org/10.1038/326711a0
25. Tyagi M, Karn J. 2007. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J 26:4985–4995. http://dx.doi.org/10.1038/sj.emboj.7601928
26. He G, Margolis DM. 2002. Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol 22:2965–2973. http://dx.doi.org/10.1128/MCB.22.9.2965-2973.2002
27. Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M, Schenkova K, Ambiel I, Wabnitz G, Gramberg T, Panitz S, Flory E, Landau NR, Sertel S, Rutsch F, Lasitschka F, Kim B, König R, Fackler OT, Keppler OT. 2012. SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat Med 18:1682–1687. http://dx.doi.org/10.1038/nm.2964
28. Gao WY, Cara A, Gallo RC, Lori F. 1993. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunode- ficiency virus type 1 replication. Proc Natl Acad Sci U S A 90:8925–8928. http://dx.doi.org/10.1073/pnas.90.19.8925
29. Lenasi T, Contreras X, Peterlin BM. 2008. Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe 4:123–133. http://dx.doi.org/10.1016/j.chom.2008.05.016
30. Van Lint C. 2000. Role of chromatin in HIV-1 transcriptional regulation. Adv Pharmacol 48:121–160. http://dx.doi.org/10.1016/S1054-3589(00)48005-1
31. Van Lint C, Emiliani S, Ott M, Verdin E. 1996. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 15:1112–1120
32. Lusic M, Giacca M. 2015. Regulation of HIV-1 latency by chromatin structure and nuclear architecture. J Mol Biol 427:688–694. http://dx.doi.org/10.1016/j.jmb.2014.07.022
33. Blazkova J, Trejbalova K, Gondois-Rey F, Halfon P, Philibert P, Guiguen A, Verdin E, Olive D, Van Lint C, Hejnar J, Hirsch I. 2009. CpG methylation controls reactivation of HIV from latency. PLoS Pathog 5:e1000554. http://dx.doi.org/10.1371/journal.ppat.1000554
34. Blazkova J, Murray D, Justement JS, Funk EK, Nelson AK, Moir S, Chun TW, Fauci AS. 2012. Paucity of HIV DNA methylation in latently infected, resting CD4+T cells from infected individuals receiving antiretroviral therapy. J Virol 86:5390–5392. http://dx.doi.org/10.1128/JVI.00040-12
35. Ho Y-C, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, Lai J, Blankson JN, Siliciano JD, Siliciano RF. 2013. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155:540–551. http://dx.doi.org/10.1016/j.cell.2013.09.020
36. Mahmoudi T, Parra M, Vries RG, Kauder SE, Verrijzer CP, Ott M, Verdin E. 2006. The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter. J Biol Chem 281: 19960–19968. http://dx.doi.org/10.1074/jbc.M603336200
37. Tréand C, du Chéné I, Brès V, Kiernan R, Benarous R, Benkirane M, Emiliani S. 2006. Requirement for SWI/SNF chromatin-remodeling complex in Tat-mediated activation of the HIV-1 promoter. EMBO J 25: 1690–1699. http://dx.doi.org/10.1038/sj.emboj.7601074
38. Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T. 1997. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci U S A 94:2927–2932. http://dx.doi.org/10.1073/pnas.94.7.2927
39. Agbottah E, Deng L, Dannenberg LO, Pumfery A, Kashanchi F. 2006. Effect of SWI/SNF chromatin remodeling complex on HIV-1 Tat activated transcription. Retrovirology 3:48. http://dx.doi.org/10.1186/1742-4690-3-48
40. Benkirane M, Chun RF, Xiao H, Ogryzko VV, Howard BH, Nakatani Y, Jeang KT. 1998. Activation of integrated provirus requires histone acetyltransferase. p300 and P/CAF are coactivators for HIV-1 Tat. J Biol Chem 273:24898–24905. http://dx.doi.org/10.1074/jbc.273.38.24898
41. Col E, Caron C, Seigneurin-Berny D, Gracia J, Favier A, Khochbin S. 2001. The histone acetyltransferase, hGCN5, interacts with and acetylates the HIV transactivator, Tat. J Biol Chem 276:28179–28184. http://dx.doi.org/10.1074/jbc.M101385200
42. Hottiger MO, Nabel GJ. 1998. Interaction of human immunodeficiency virus type 1 Tat with the transcriptional coactivators p300 and CREB binding protein. J Virol 72:8252–8256
43. Marzio G, Tyagi M, Gutierrez MI, Giacca M. 1998. HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. Proc Natl Acad Sci U S A 95:13519–13524. http://dx.doi.org/10.1073/pnas.95.23.13519
44. Demarchi F, Gutierrez MI, Giacca M. 1999. Human immunodeficiency virus type 1 tat protein activates transcription factor NF-kB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR. J Virol 73:7080–7086
45. Razooky BS, Pai A, Aull K, Rouzine IM, Weinberger LS. 2015. A hardwired HIV latency program. Cell 160:990–1001. http://dx.doi.org/10.1016/j.cell.2015.02.009
46. Yukl S, Pillai S, Li P, Chang K, Pasutti W, Ahlgren C, Havlir D, Strain M, Günthard H, Richman D, Rice AP, Daar E, Little S, Wong JK. 2009. Latently infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity. Virology 387:98–108. http://dx.doi.org/10.1016/j.virol.2009.01.013
47. Mousseau G, Mediouni S, Valente ST. 2015. Targeting HIV transcription: the quest for a functional cure. Curr Top Microbiol Immunol 389:121–145 http://dx.doi.org/10.1007/82_2015_435
48. Mousseau G, Clementz MA, Bakeman WN, Nagarsheth N, Cameron M, Shi J, Baran P, Fromentin R, Chomont N, Valente ST. 2012. An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tatdependent HIV transcription. Cell Host Microbe 12:97–108. http://dx.doi.org/10.1016/j.chom.2012.05.016
49. Pasternak AO, Adema KW, Bakker M, Jurriaans S, Berkhout B, Cornelissen M, Lukashov VV. 2008. Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol 46:2206–2211. http://dx.doi.org/10.1128/JCM.00055-08
50. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS. 1998. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 188:83–91. http://dx.doi.org/10.1084/jem.188.1.83
51. Scripture-Adams DD, Brooks DG, Korin YD, Zack JA. 2002. Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol 76: 13077–13082. http://dx.doi.org/10.1128/JVI.76.24.13077-13082.2002
52. Wang FX, Xu Y, Sullivan J, Souder E, Argyris EG, Acheampong EA, Fisher J, Sierra M, Thomson MM, Najera R, Frank I, Kulkosky J, Pomerantz RJ, Nunnari G. 2005. IL-7 is a potent and proviral strainspecific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 115:128–137. http://dx.doi.org/10.1172/JCI22574
53. Chan JK, Greene WC. 2012. Dynamic roles for NF-kB in HTLV-I and HIV-1 retroviral pathogenesis. Immunol Rev 246:286–310. http://dx.doi.org/10.1111/j.1600-065X.2012.01094.x
54. Pessler F, Cron RQ. 2004. Reciprocal regulation of the nuclear factor of activated T cells and HIV-1. Genes Immun 5:158–167. http://dx.doi.org/10.1038/sj.gene.6364047
55. Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, Greene WC, Kashuba A, Lewin SR, Margolis DM, Mau M, Ruelas D, Saleh S, Shirakawa K, Siliciano RF, Singhania A, Soto PC, Terry VH, Verdin E, Woelk C, Wooden S, Xing S, Planelles V. 2013. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog 9:e1003834. http://dx.doi.org/10.1371/journal.ppat.1003834
56. Mbonye U, Karn J. 2011. Control of HIV latency by epigenetic and non-epigenetic mechanisms. Curr HIV Res 9:554–567. http://dx.doi.org/10.2174/157016211798998736
57. Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV. 2005. Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell 122:169–182. http://dx.doi.org/10.1016/j.cell.2005.06.006
58. Hocqueloux L, Prazuck T, Avettand-Fenoel V, Lafeuillade A, Cardon B, Viard JP, Rouzioux C. 2010. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 24:1598–1601. http://dx.doi.org/10.1097/QAD.0b013e32833b61ba
59. Butera ST, Perez VL, Wu BY, Nabel GJ, Folks TM. 1991. Oscillation of the human immunodeficiency virus surface receptor is regulated by the state of viral activation in a CD4+ cell model of chronic infection. J Virol 65:4645–4653
60. Jordan A, Bisgrove D, Verdin E. 2003. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 22: 1868–1877. http://dx.doi.org/10.1093/emboj/cdg188
61. Chávez L, Kauder S, Verdin E. 2011. In vivo, in vitro, and in silico analysis of methylation of the HIV-1 provirus. Methods 53:47–53. http://dx.doi.org/10.1016/j.ymeth.2010.05.009
62. Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E. 2009. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 5:e1000495. http://dx.doi.org/10.1371/journal.ppat.1000495
63. Chatila T, Silverman L, Miller R, Geha R. 1989. Mechanisms of T cell activation by the calcium ionophore ionomycin. J Immunol 143: 1283–1289
64. Siekevitz M, Josephs SF, Dukovich M, Peffer N, Wong-Staal F, Greene WC. 1987. Activation of the HIV-1 LTR by T cell mitogens and the transactivator protein of HTLV-I. Science 238:1575–1578. http://dx.doi.org/10.1126/science.2825351
65. Hiscott J, Marois J, Garoufalis J, D’Addario M, Roulston A, Kwan I, Pepin N, Lacoste J, Nguyen H, Bensi G, et al. 1993. Characterization of a functional NF-kappa B site in the human interleukin 1bpromoter: evidence for a positive autoregulatory loop. Mol Cell Biol 13:6231–6240
66. Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marmé D, Rapp UR. 1993. Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 364:249–252. http://dx.doi.org/10.1038/364249a0
67. Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, Le Gall S, Rinaldo CR, Craggs SL, Allgaier RL, Power KA, Kuntzen T, Tung CS, LaBute MX, Mueller SM, Harrer T, McMichael AJ, Goulder PJ, Aiken C, Brander C, Kelleher AD, Allen TM. 2007. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol 81:12382–12393. http://dx.doi.org/10.1128/JVI.01543-07
68. McKernan LN, Momjian D, Kulkosky J. 2012. Protein kinase C: one pathway towards the eradication of latent HIV-1 reservoirs. Adv Virol 2012:805347. http://dx.doi.org/10.1155/2012/805347
69. Williams SA, Chen LF, Kwon H, Fenard D, Bisgrove D, Verdin E, Greene WC. 2004. Prostratin antagonizes HIV latency by activating NF-kB. J Biol Chem 279:42008–42017. http://dx.doi.org/10.1074/jbc.M402124200
70. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. 2009. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 25: 207–212. http://dx.doi.org/10.1089/aid.2008.0191
71. Clouse KA, Powell D, Washington I, Poli G, Strebel K, Farrar W, Barstad P, Kovacs J, Fauci AS, Folks TM. 1989. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol 142:431–438
72. Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, Fauci AS. 1989. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A 86:2365–2368. http://dx.doi.org/10.1073/pnas.86.7.2365
73. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS. 1987. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 238:800–802. http://dx.doi.org/10.1126/science.3313729
74. Cannon P, Kim SH, Ulich C, Kim S. 1994. Analysis of Tat function in human immunodeficiency virus type 1-infected low-level-expression cell lines U1 and ACH-2. J Virol 68:1993–1997
75. Emiliani S, Van Lint C, Fischle W, Paras P, Jr., Ott M, Brady J, Verdin E. 1996. A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency. Proc Natl Acad SciUSA93:6377–6381. http://dx.doi.org/10.1073/pnas.93.13.6377
76. Emiliani S, Fischle W, Ott M, Van Lint C, Amella CA, Verdin E. 1998. Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. J Virol 72: 1666–1670
77. Reza SM, Rosetti M, Mathews MB, Pe’ery T. 2003. Differential activation of Tat variants in mitogen-stimulated cells: implications for HIV-1 postintegration latency. Virology 310:141–156. http://dx.doi.org/10.1016/S0042-6822(03)00106-5
78. Adams M, Sharmeen L, Kimpton J, Romeo JM, Garcia JV, Peterlin BM, Groudine M, Emerman M. 1994. Cellular latency in human immunode- ficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. Proc Natl Acad Sci U S A 91:3862–3866. http://dx.doi.org/10.1073/pnas.91.9.3862
79. Adams M, Wong C, Wang D, Romeo J. 1999. Limitation of Tatassociated transcriptional processivity in HIV-infected PBMC. Virology 257:397–405. http://dx.doi.org/10.1006/viro.1999.9647
80. Ambrosino C, Ruocco MR, Chen X, Mallardo M, Baudi F, Trematerra S, Quinto I, Venuta S, Scala G. 1997. HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors. J Biol Chem 272:14883–14892. http://dx.doi.org/10.1074/jbc.272.23.14883
81. Chen R, Liu M, Li H, Xue Y, Ramey WN, He N, Ai N, Luo H, Zhu Y, Zhou N, Zhou Q. 2008. PP2B and PP1acooperatively disrupt 7SK snRNP to release P-TEFb for transcription in response to Ca2+ signaling. Genes Dev 22:1356–1368. http://dx.doi.org/10.1101/gad.1636008
82. Chun RF, Semmes OJ, Neuveut C, Jeang KT. 1998. Modulation of Sp1 phosphorylation by human immunodeficiency virus type 1 Tat. J Virol 72:2615–2629
83. Verhoef K, Koper M, Berkhout B. 1997. Determination of the minimal amount of Tat activity required for human immunodeficiency virus type 1 replication. Virology 237:228–236. http://dx.doi.org/10.1006/viro.1997.8786
84. Meyerhans A, Cheynier R, Albert J, Seth M, Kwok S, Sninsky J, Morfeldt-Månson L, Asjö B, Wain-Hobson S. 1989. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell 58:901–910 http://dx.doi.org/10.1016/0092-8674(89)90942-2
85. Sabino E, Cheng-Mayer C, Mayer A. 1993. An individual with a high prevalence of a tat-defective provirus in peripheral blood. AIDS Res Hum Retroviruses 9:1265–1268. http://dx.doi.org/10.1089/aid.1993.9.1265
86. Donahue DA, Kuhl BD, Sloan RD, Wainberg MA. 2012. The viral protein Tat can inhibit the establishment of HIV-1 latency. J Virol 86: 3253–3263. http://dx.doi.org/10.1128/JVI.06648-11
87. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487:482–485. http://dx.doi.org/10.1038/nature11286
88. Deeks SG. 2012. HIV: shock and kill. Nature 487:439–440. http://dx.doi.org/10.1038/487439a
89. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, Zhang H, Margolick JB, Blankson JN, Siliciano RF. 2012. Stimulation of HIV-1- specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36:491–501. http://dx.doi.org/10.1016/j.immuni.2012.01.014
90. Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, Smith MZ, Spelman T, McMahon J, Velayudham P, Brown G, Roney J, Watson J, Prince MH, Hoy JF, Chomont N, Fromentin R, Procopio FA, Zeidan J, Palmer S, Odevall L, Johnstone RW, Martin BP, Sinclair E, Deeks SG, Hazuda DJ, Cameron PU, Sekaly RP, Lewin SR. 2014. Activation of HIV transcription with short-course vorinostat in HIVinfected patients on suppressive antiretroviral therapy. PLoS Pathog 10: e1004473. http://dx.doi.org/10.1371/journal.ppat.1004473
91. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, Macken CA, Perelson AS, Markowitz M, Ho DD. 2000. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy. Nat Med 6:82–85. http://dx.doi.org/10.1038/71577.